MAP2K7 and juvenile myelomonocytic leukemia: Germline and somatic Ras/MAPK mutations largely define JMML24,30,52,53 and our data suggest a higher degree of genomic similarity between JMML and pediatric RAEB than previously appreciated, which could have beneficial clinical implications given the new clinical trial with a MEK inhibitor in JMML (Children’s Oncology Group ADVL1521).